Atopic eczema

Current Allergy and Asthma Reports

Volumn 6, Issue 6, 2006, Pages 445-447

  Mörenschlager, Matthias ^a   Ring, Johannes ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; CALCINEURIN INHIBITOR; CEPHALOSPORIN; CHINESE DRUG; CHLORHEXIDINE; CORTICOSTEROID; CYCLOSPORIN; DIMETINDENE; DOXYLAMINE; EMOLLIENT AGENT; HERBACEOUS AGENT; HYDROCORTISONE BUTYRATE; HYDROXYZINE; PENICILLIN G; PIMECROLIMUS; PREDNICARBATE; PROMETHAZINE; SILVER; TACROLIMUS; TRICLOSAN;

ALTERNATIVE MEDICINE; ATOPIC DERMATITIS; CHINESE MEDICINE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENETIC RISK; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HYPERTENSION; HYPNOSIS; LYMPHOMA; MAINTENANCE THERAPY; MASSAGE; MUTAGENICITY; NEPHROTOXICITY; NONHUMAN; NOTE; NUTRITIONAL SUPPORT; PATCH TEST; PATHOGENESIS; PATIENT EDUCATION; PHOTOTHERAPY; PRICK TEST; PSYCHOPHYSIOLOGY; PSYCHOTHERAPY; RISK ASSESSMENT; SKIN CANCER; TOPICAL TREATMENT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

DERMATITIS, ATOPIC; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; PATIENT EDUCATION; PREVALENCE;

EID: 33750290665     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-006-0016-5     Document Type: Note

References (36)

1. Ring J: Allergy in Practice. Heidelberg: Springer, 2005.
2. Friedmann PS, Holden CA: Atopic dermatitis. In Rook's Textbook of Dermatology, edn 7. Edited by Burns T, Breathnach S, Cox N, Griffiths C. Oxford: Blackwell, 2006.
3. Ring J, Krämer U, Schäfer T, Behrendt H: Why are allergies increasing? Curr Opinion Immunol 2001, 13:701-708.
4. Wüthrich B: Epidemiology and natural history of atopic dermatitis. Allergy Clin Immunol Int 1996, 9:77-82.
5. Schultz-Larsen F: Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1993, 28:719-723.
6. Cookson WO, Moffatt MF: The genetics of atopic dermatitis. Curr Opin Allergy Immunol 2002, 2:383-387.
7. Leung DYM, Jain N, Leo HL: New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol 2003, 15:634-638.
8. Tamura K, Suzuki M, Arakawa H, et al.: Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int Arch Allergy Immunol 2003, 131:33-38.
9. Novak N, Kruse S, Kraft S, et al.: Dichotomic nature of atopic dcrmatitis refiected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic dermatitis. J Invest Dermatol 2002, 119:870-875.
10. Arkwright PD, Chase JM, Babbagc S, et al.: Atopic dermatitis is associated with a low-producer transforming growth factor beta(l) cytokine genotype. J Allergy Clin Immunol 2001, 108:281-284.
11. Yagi R, Nagai H, Iigo Y, et al.: Development of atopic dermatitis-skin lesions in STAT6-deficient NC/Nga mice. J Immunol 2002, 168:2020-2027.
12. Sandford AJ, Shirakawa T, Moffatt MF, et al.: Localisation of atopy and beta subunit of high-affinity IgE receptor (Fc epsilon RI) on chromosome 11q. Lancet 1993, 341:332-334.
13. Weidinger S, Klopp N, Wagenpfeil S, et al.: Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet 2004, 41:658-663.
14. Wiliams HC: Atopic dermatitis. N Engl J Med 2005, 352:2314-2324.
15. Sampson HA, Albergo R: Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis. J Allergy Clin Immunol 1984, 74:26-33.
16. Darsow U, Laifaoui J, Kerschenloh K, et al.: The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 2004, 59:1318-1325.
17. Darsow U, Ring J: Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests. Clin Exp Dermatol 2000,25:544-551.
18. Möhrenschlager M, Schäfer T, Huss-Marp J. et al.: The course of eczema in children aged 5-7 years and its relation to atopy: differences between boys and girls. Br J Dermatol 2006, 154:505-513.
19. Abeck D. Burgdorf W, Cremer H: Common Skin Diseases in Children. Darmstadt: Steinkopff, 2003.
20. Wollenberg A, Sharma S, von Bubnoff D, et al.: Topical tacrolimus (FK 506) leads to profound phenotypic, alterations of epidermal antigen-presenting dendritic. cells in atopic dermatitis. J Allergy Clin Immunol 2001, 107:519-525.
21. Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001, 107:345-352.
22. Zuberbier T, Chong SU, Grunow K, et al.: The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001, 108:275-280.
23. Reitamo S, Van Leent EJ, Ho V, et al.: Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002, 109:539-546.
24. Reitamo S, Harper J, Bos JD, et al.: 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004, 150:554-562.
25. Eichenfield LF, Lucky AW, Boguniewicz M, et al.: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002, 46:495-504.
26. Center for Drug Evaluation and Research: Alert for healthcare professionals: pimecrolimus (marketed as Elidel). Rockville, MD: Food and Drug Administration; March 2005.
27. Center for Drug Evaluation and Research: Alert for healthcare professionals: taccrolimus (marketed as Protopic). Rockville, MD: Food and Drug Administration; March 2005.
28. Food and Drug Administration Pediatric Advisory Committee: February IS, 2005, Briefing Information. http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4089b2.htm. Accessed August 4, 2006.
29. Allen BR, Lakhanpaul M, Morris A, et al.: Systemic exposure, tolerability and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003, 88:969-973.
30. Bieber T, Cork M, Ellis C, et al.: Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005,211:77-78.
31. Mallon E, Powell S, Bridgman A: Wet-wrap dressings for the treatment of atopic eczema in the community. J Dermatol Treat 1994, 5:97-98.
32. Keane FM, Munn SE, du Vivier AWP, et al.: Analysis of Chinese herbal creams prescribed for dermatological conditions. BMJ 1999, 318:563-564.
33. McMenamy CJ, Katz RC, Gipson M: Treatment of eczema by EMG biofeedback and relaxation training: a multiple baseline analysis. J Behav Ther Exp Psychiatry 1988, 19:221-227.
34. Schachner L, Field T, Hernandez-Reif M, et al.: Atopic dermatitis symptoms decreased in children following massage therapy. Ped Dermatol 1998, 15:390-395.
35. Senser C, Habermüller M, Revenstorf D: Hypnotherapie bei atopischer Dermatitis. Akt Dermatol 2004, 30:103-108.
36. Staab D, Diepgen TL, Fartasch M, et al.: Age-related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006, 332:933-938.